文献速递免疫规划慢病防控与筛查

美国50-64岁商业保险免疫功能正常与免疫功能低下成人中重组带状疱疹疫苗的使用模式

Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
PubMed 文献 · Vaccine · 2022-11-14

基于IBM MarketScan数据库2018年1月1日至2019年12月31日理赔数据,分析美国50-64岁成人重组带状疱疹疫苗(RZV)接种情况。研究期间RZV启动累积发生率为10.0%,免疫功能低下者启动率高于免疫功能正常者,启动者中89.5%完成两剂,88.6%完成者在推荐接种程序内完成。

要点

  • 研究期间50-64岁成人RZV启动累积发生率为10.0%,启动率随年龄和就诊次数增加而升高。
  • 免疫功能低下成人RZV启动率高于免疫功能正常成人,其中HIV和原发性免疫缺陷者启动率最高。
  • 启动RZV者中89.5%完成两剂,完成者中88.6%在推荐接种程序内完成。

核心结论

  • CDC推荐后两年内50-64岁成人RZV接种率低,且因人口学、医疗可及性和临床特征而异。
  • 尽管研究期间CDC未对免疫功能低下成人作出专门推荐,该人群RZV启动率仍高于免疫功能正常成人。
  • CDC此后已推荐免疫功能低下个体接种RZV,本研究结果可能有助于提高重症高风险个体的RZV接种率。

研究设计与样本

  • 利用IBM MarketScan数据库2018年1月1日至2019年12月31日理赔数据识别RZV接种记录。
  • 以研究开始前6个月住院、门诊和处方理赔将参保人分为免疫功能低下(恶性肿瘤、HIV、实体器官移植、原发性免疫抑制或药物诱导免疫抑制)与免疫功能正常。
  • 分析美国50-64岁成人首剂RZV启动和两剂完成随时间的变化,以及免疫功能对RZV接种的影响。

主要发现

  • 研究期间RZV启动累积发生率为10.0%。
  • RZV启动率随年龄和就诊次数增加而升高,女性、城市居民、高免赔额保险受益人和免疫功能低下者中更高。
  • 免疫功能低下成人中,HIV和原发性免疫缺陷者RZV启动率最高。
  • 启动RZV者中89.5%完成两剂,完成率在药房接种首剂者中最高。
  • 完成RZV接种者中88.6%在推荐接种程序内完成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Centers for Disease Control and Prevention (CDC) recommends recombinant zoster vaccination (RZV) for adults ≥ 50 years to prevent herpes zoster (HZ) and its sequelae. Initially, no distinct recommendation was made for immunocompromised adults, who experience higher HZ rates and more severe outcomes. We characterized receipt of first RZV dose (initiation) and both doses (completion) over time, and the impact of immune function on RZV uptake among adults aged 50-64 years in the United States. METHODS: We identified RZV claims from the IBM MarketScan database between 1/1/2018 and 12/31/2019. We characterized immunocompromised enrollees as having malignancy, HIV, solid organ transplant, primary immunosuppression, or medication-induced immunosuppression using inpatient, outpatient, and prescription claims in the 6 months prior to study start. We evaluated patterns of vaccine uptake by demographic and healthcare access characteristics and immune status. RESULTS: The cumulative incidence of RZV initiation during the study period was 10.0%. Incidence increased with age and number of medical office visits, and was higher among women, urban residents, high-deductible insurance beneficiaries, and those who were immunocompromised compared to immunocompetent. Among immunocompromised adults, RZV initiation was highest among those with HIV and primary immunodeficiencies. Of those who initiated RZV, 89.5% received both doses. RZV completion was highest among those who received the first dose at a pharmacy. Most enrollees (88.6%) who completed RZV vaccination did so within the recommended dosing schedule. CONCLUSIONS: RZV uptake was low in the two years since the CDC recommendation, and differed by demographic, healthcare access, and clinical characteristics. Initiation rates were higher among immunocompromised adults compared to immunocompetent adults, despite no CDC recommendation for vaccination in these groups during the study period. The CDC has since recommended RZV for immunocompromised individuals, and our findings may inform efforts to increase RZV uptake in individuals at higher risk of severe disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fix J, Vielot NA, Lund JL, et al. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States. Vaccine. 2022. PMID: 36396511. doi:10.1016/j.vaccine.2022.10.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。